Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Gray matter SWI-filtered phase and atrophy are linked to disability in MS .
The challenge of comorbidity in clinical trials for multiple sclerosis.
The influence of disease duration, clinical course, and immunosuppressive therapy on the synthesis of intrathecal oligoclonal IgG bands in multiple sclerosis.
Oral Tolerance Induction in Experimental Autoimmune Encephalomyelitis with Candida utilis Expressing the Immunogenic MOG35-55 Peptide.
Glatiramer acetate (GA) prevents TNF-α-induced monocyte adhesion to primary endothelial cells through interfering with the NF-κB pathway.
Identical lesion morphology in primary progressive and relapsing-remitting MS -an ultrahigh field MRI study.
SigmaPharm Laboratories Products
Gpr126 functions in Schwann cells to control differentiation and myelination via G-protein activation.
A randomized controlled phase II trial of riluzole in early multiple sclerosis.
Alterations in serum MMP-8, MMP-9, IL-12p40 and IL-23 in multiple sclerosis patients treated with interferon-beta1b.
Boxed warning of HBV risk added to Rituxan, Arezerra
Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results.
Dimethyl fumarate inhibits integrin α4 expression in multiple sclerosis models.
In vivo time-lapse imaging shows dynamic oligodendrocyte progenitor behavior during zebrafish development.
Multifocal Tumefactive Demyelination Mimicking Intracranial Neoplasm.
Nanoparticle transport across the blood brain barrier.
Primary infection with the Epstein-Barr virus and risk of multiple sclerosis.
A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis.
Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis?
How many injections did you miss last month? A simple question to predict interferon β-1a adherence in multiple sclerosis.
Biogen Idec receives notification of PDUFA date extension for PLEGRIDY™ (peginterferon beta-1a)
Rituximab Efficiently Depletes Increased CD20-Expressing T Cells in Multiple Sclerosis Patients.
Biologics-induced autoimmune diseases.
Subcutaneous recombinant interferon-β-1a (Rebif®): a review of its use in the treatment of relapsing multiple sclerosis.
Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria.

Pages